一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

AMPRENAVIR

AMPRENAVIR Struktur
161814-49-9
CAS-Nr.
161814-49-9
Englisch Name:
AMPRENAVIR
Synonyma:
VX 478;PROZEI;141W94;KVX-478;CS-1052;AGENERASE;AMPRENAVIR;Angenerase;Amprenavir 13C6;5-Bromo-5-nitro-1
CBNumber:
CB4186139
Summenformel:
C25H35N3O6S
Molgewicht:
505.63
MOL-Datei:
161814-49-9.mol

AMPRENAVIR Eigenschaften

Schmelzpunkt:
72-74°C
Dichte
1.30±0.1 g/cm3(Predicted)
storage temp. 
-20°C
L?slichkeit
DMSO: soluble20mg/mL, clear
Aggregatzustand
powder
pka
11.54±0.46(Predicted)
Farbe
white to beige
Optische Rotation
[α]/D +8 to +12°, c = 0.5 in methanol
BCS Class
2
InChIKey
YMARZQAQMVYCKC-OEMFJLHTSA-N
SMILES
[S](=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]3COCC3)Cc2ccccc2)CC(C)C)c1ccc(cc1)N
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
RIDADR  3077
WGK Germany  3
HS Code  29350090
Speicherklasse 11 - Combustible Solids
Giftige Stoffe Daten 161814-49-9(Hazardous Substances Data)
Bildanzeige (GHS) Exclamation Mark (GHS07)
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitssch?dlich bei Verschlucken. Akute Toxizit?t oral Kategorie 4 Warnung P264, P270, P301+P312, P330, P501
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung P264, P280, P305+P351+P338,P337+P313P
H332 Gesundheitssch?dlich bei Einatmen. Akute Toxizit?t inhalativ Kategorie 4 Warnung P261, P271, P304+P340, P312
H335 Kann die Atemwege reizen. Spezifische Zielorgan-Toxizit?t (einmalige Exposition) Kategorie 3 (Atemwegsreizung) Warnung
Sicherheit
P261 Einatmen von Staub vermeiden.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.

AMPRENAVIR Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Amprenavir was launched as Agenerase in the US for the treatment of AIDS patients in combination with approved agent antiretroviral nucleoside analogs. It is the fifth non-peptidic inhibitor of HIV-1 protease to be marketed in this indication after the last approved Neflinavir. Amprenavir, designed via a structure-based process, is the smallest molecule in the 《navir》 class and exhibits a reduced peptidic character. An improved process for preparation comprising four steps from a (1S, 2R)-2-hydroxy-3-aminopropylcarbamate has been developed. Amprenavir is a potent inhibitor of HIV-1 aspartyl protease (Ki = 0.6nM), an enzyme required by the virus to cleave pro-form polyproteins to structural proteins during the last stage in the replication process. The compound displays good oral bioavailability in humans and penetrates the CNS, which is an important advantage in long-term treatment. Its plasma half-life is approximately 10h. Treatment with Amprenavir in combination with nucleoside analog reverse transcriptase inhibitors considerably decreases viral load and restores CD4+ T-cell counts in patients with HIV infection.

Chemische Eigenschaften

Off-White to Pale Yellow

Verwenden

A selective HIV protease inhibitor. An analogue of Ritonavir

Indications

Amprenavir (Agenerase) is administered twice daily, providing the patient with an advantage over other protease inhibitors that must be taken more frequently (e.g., indinavir, saquinavir). Common side effects of am-prenavir include nausea, vomiting, diarrhea, and perioral paraesthesias. Rash occurs in approximately 20 to 30% of patients and can be mild or severe (Stevens- Johnson syndrome).

Acquired resistance

Mutations at position 50, 76 and 84 of the protease enzyme gene are associated with significantly reduced susceptibility.

Allgemeine Beschreibung

Amprenavir is a second-generation drug derived from hydroxyethylamine sulfonamide.

Pharmazeutische Anwendungen

A synthetic compound formulated as the calcium salt of the oral prodrug fosamprenavir.

Pharmakokinetik

Oral absorption: Not known/available
Cmax 700 mg + ritonavir 100 mg:c. 6.08 mg/L
twice daily
Cmin 700 mg + ritonavir 100 mg:c. 2.12 mg/L
twice daily
Plasma half-life: c. 7.7 h
Volume of distribution: c. 430 L
Plasma protein binding: c. 90%
Absorption
Fosamprenavir is rapidly and almost completely hydrolyzed to amprenavir and inorganic phosphate by cellular phosphatases in the gut epithelium as it is absorbed. Absolute bioavailability has not been established. It can be taken without regard to food.
Distribution
It penetrates moderately well into the CNS. The semen:plasma ratio is negligible. It is not known if it is distributed into breast milk.
Metabolism and excretion
It is extensively metabolized by the cytochrome P450 (CYP) 3A4 enzyme system. Two major metabolites have been identified that appear to result from the oxidation of the tetrahydrofuran and aniline moieties. Around 14% of a dose is eliminated in the urine and 75% in feces, <3% as unchanged drug. Metabolites account for >90% of administered drug found in fecal samples. It should be used with caution and at reduced doses in adults with mild or moderate hepatic impairment; it is contraindicated in patients with severe hepatic impairment.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Nebenwirkungen

The most common adverse events in patients receiving boosted fosamprenavir were diarrhea, nausea, headache, fatigue, vomiting and rash. Ritonavir-boosted fosamprenavir is associated with a dyslipidemia profile characteristic of those treated with other protease inhibitors boosted with 200 mg of ritonavir.

AMPRENAVIR Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


AMPRENAVIR Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 229)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806
sales@capot.com China 29640 60
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 965 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63687 58
TargetMol Chemicals Inc.
+1-781-999-5354; +17819995354
marketing@targetmol.com United States 32466 58
HANGZHOU CLAP TECHNOLOGY CO.,LTD
86-571-88216897,88216896 13588875226
sales@hzclap.com CHINA 6312 58
Shaanxi Dideu Medichem Co. Ltd
+86-029-89586680 +86-18192503167
1026@dideu.com China 9996 58
AFINE CHEMICALS LIMITED
+86-571-85134551
info@afinechem.com China 15083 58
Baoji Guokang Healthchem Co., Ltd.
+86-0917-3909592 +86-13892490616
gksales1@gk-bio.com China 9067 58
BOC Sciences
16314854226; +16314854226
inquiry@bocsci.com United States 19853 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471;
sales@sarms4muscle.com China 10473 58

  • KVX-478
  • AGENERASE
  • AMPRENAVIR
  • 141W94
  • PROZEI
  • 141W94, KVX-478, Agenerase, Prozei,
  • Carbamic acid, (1S,2R)-3-(4-aminophenyl)sulfonyl(2-methylpropyl)amino-2-hydroxy-1-(phenylmethyl)propyl-, (3S)-tetrahydro-3-furanyl ester
  • Angenerase
  • Carbamic acid, [3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, tetrahydro-3-furanyl ester, [3S-[3R*(1R*,2S*)]]-
  • VX 478
  • [(3S)-Oxolan-3-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
  • N-[(1S,2R)-3-[[(4-AMinophenyl)sulfonyl](2-Methylpropyl)aMino]-2-hydroxy-1-(phenylMethyl)propyl]carbaMic Acid (3S)-Tetrahydro-3-furanyl Ester
  • AMprenavir(agenerase)
  • Amprenavir(KVX-478)
  • AMPRENAVIR (VX-478)
  • CS-1052
  • (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate
  • Carbamic acid, N-[(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3S)-tetrahydro-3-furanyl ester
  • AMPRENAVIR USP/EP/BP
  • Amprenavir 13C6
  • AmprenavirQ: What is Amprenavir Q: What is the CAS Number of Amprenavir Q: What is the storage condition of Amprenavir Q: What are the applications of Amprenavir
  • 5-Bromo-5-nitro-1
  • (S)-Tetrahydrofuran-3-yl ((2S,3R)-4-((4-amino-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate
  • Amprenavir, 10 mM in DMSO
  • 161814-49-9
  • C25H35N3O6S
  • Inhibitor
  • peptides
  • API
  • Anti-viral Compounds
  • Anti-virals
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Non-nucleoside Reverse Transcriptase
  • Pharmaceuticals
Copyright 2019 ? ChemicalBook. All rights reserved
绥中县| 新泰市| 岫岩| 茶陵县| 临颍县| 宁化县| 来凤县| 凤山县| 成武县| 稷山县| 重庆市| 浦县| 通辽市| 陇南市| 上虞市| 芜湖县| 乐安县| 珠海市| 苏尼特右旗| 聂荣县| 清河县| 拜泉县| 北宁市| 陈巴尔虎旗| 衡水市| 如皋市| 黔东| 宝坻区| 安阳市| 墨江| 邵阳市| 青铜峡市| 天全县| 府谷县| 油尖旺区| 兴仁县| 南召县| 绥江县| 长垣县| 龙川县| 元朗区|